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INTRODUCTION
Prostate cancer (PCa) is the second most commonly 
diagnosed cancer [1]. The majority of patients are diagnosed 
in potentially cureable early stages [2]. Standard local 
treatment options include active surveillance, radical 
prostatectomy (RP) and radiotherapy (RT), that can be 
delivered via external beam (EBRT) and/or brachytherapy 
(BT) [3]. According to the Surveillance, Epidemiology and 
End Results database the distribution of these treatment 
options in men with newly diagnosed PCa is the following: 
RP, 36%; EBRT, 20%; BT, 10%; EBRT+BT, 4% [4]. For 
localized disease, 5-year survival rates for these therapies 
alone or in combination reach almost a 100%; however, side 
effects associated with each treatment vary significantly 
[5,6]. Due to the high survival rates, the number of prostate 
cancer survivors in the United States annually increased by 
200,000 men up to almost 2.8 millions in 2012, leaving a large 
cohort of men at risk for short and/or long-term side effects 
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of their cancer treatment [6]. Despite significant advances 
in techniques for RT delivery (e.g., intensity modulated 
radiation therapy, IMRT), some patients treated with RT 
may suffer from long-term genitourinary side effects [7] 
and significant quality of life impact [4,8]. Particular the 
development of  urethral stricture is a delicate problem. 
It occurs in about 2% of  patients undergoing EBRT, 4% 
for BT and 11% of EBRT-BT combination therapy [4]. In 
addition, due to its specific pathophysiology, the treatment 
of  radiation-induced urethral strictures is complex and 
demands some operative skills. 
PATHOPHYSIOLOGY OF RADIOTHERAPY
Radiation causes ionization events and production 
of  free radicals resulting in dif ferent types of  DNA 
damage. DNA double-strand brakes (DSB) are generally 
thought to represent the principal lethal events and the 
most critical lesions to RT. DSBs initiate a complex set of 
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cellular responses including DNA damage recognition and 
transduction of the signal, resulting in many downstream 
effects including cell cycle checkpoint activation, induction 
and coordination of stress response genes, DNA repair, and/
or activation of the apoptotic cascade [9]. The consequential 
cell death is generally caused by improperly repaired 
DNA damage and/or the induction of apoptosis. Moreover 
radiation activates pro-inflammatory and pro-f ibrotic 
cytokines leading to vascular injury (endarteritis) and 
stem cell damage. The tissue responds with features of 
failed wound healing like vascular atrophy leading to 
poorly oxygenated tissue and/or collagen deposition with 
eventual tissue scarring [10]. Epithelial leakage allows 
extravastation of  urine causing a fibrotic reaction. The 
induced inflammation processes lead to the proliferation of 
myofibroblasts, loss of smooth muscle cells and microvessels 
and collagen synthesis [11]. Consequential late effects may 
occur where severe early reactions have led to impaired 
tissue recovery. In order to facilitate cross-comparisons 
between investigators and institutions several systems 
for documenting normal tissue responses to RT have been 
developed. These include the Radiation Therapy Oncology 
Group/European Organization for Research and Treatment 
of Cancer classification, the Common Terminology Criteria 
for Adverse Events (CTCAE v4) scale and the (LENT/
SOMA) Late Effects Normal Tissue Task Force Subjective, 
Objective, Management, and Analytic system, specifically 
designed to score late reactions [12].
DOSIMETRIC ANALYSES
Several randomized clinical trials have shown that dose-
escalated RT to the prostate gland resulted in improved 
biochemical and local controls. However, this improvement 
in outcomes is often associated with increased rates of 
urinary toxicity [13-15]. Merrick et al. [15] revealed in a series 
with low-dose rate (LDR) BT patients that urethral stricture 
correlates highly with the radiation dose to the membranous 
urethra. In addition he described the dose applied 20 
mm distal to the apex as independent risk factor for the 
development of  urethral strictures. In a high-dose rate 
(HDR) series comparing 3 different fractionation schedules, 
the importance of the fractionation schedule and a higher 
urethral D10 (defined as the minimum dose received by the 
‘‘hottest’’ 10% of the urethral volume) was demonstrated. 
Higher stricture rates were observed after 19 Gy in 2 
fractions as compared to 18 Gy in 3 and 20 Gy in 4 fractions 
[16]. Another cohort of HDR patients treated as monotherapy 
with 4 fractions of 9.5 Gy within 48 hours showed very high 
rates of late genitourinary toxicity. The actuarial proportion 
of patients with late grade 3 toxicity at 5 years was 17.7%. 
Six out of  36 patients had a bulbar urethral stricture 
requiring urethral dilatation. Late grade 3 toxicity was 
associated with urethral V120 (urethral volume receiving 
≥120% of the prescribed dose) [17]. Several factors influence 
the incidence of urethral strictures in RT patients, but it 
appears that rates are higher in EBRT-HDR compared with 
LDR-BT [18]. Nevertheless it is very important to properly 
select the patients for each specific modality, to strictly 
respect the urethral doses below the recommended dose 
constraints as well as to keep a rigorous quality assurance 
on the processes of RT planning and delivery. 
CHARACTERISTICS OF URETHRAL 
STRICTURE AFTER RADIOTHERAPY
The overall reported incidence of urethral stricture after 
RT for PCa varies between 0%–18 % [4,19]. The majority of 
series report rates after BT between 3%–10% [8,20], 1%–12% 
after EBRT [4,21,22] and higher rates after the combination 
of  both. However, more recent data using modern LDR-
BT and IMRT techniques describe lower rates down to 3% 
[23,24]. In a series by Mohammed et al. [18] stricture rates 
after high dose BT were higher (11%) compared to LDR-BT 
(4%) and EBRT (2%). Reported stricture rates also increase 
with longer follow-up periods. Results from the CaPSURE 
database published by Elliott et al. [19] revealed a correlation 
of stricture incidence and time showing that the stricture 
rate increased from 1% directly after treatment to 16% after 
4 years (Table 1).
Urethral stricture after RT is a late complication usually 
observed 1–3 years after radiation. Several risk factors for 
the development of a urethral stricture have been identified. 
Previous transurethral resection of  the prostate (TURP) 
increases the stricture rates up to 15% compared to 6% 
without prior resection [25,26]. Interestingly the history of 
arterial hypertension in combination with diabetes mellitus 
is also a predictive factor, as this may lead to reduced 
blood supply due to changes in microcirculation. This 
explanation might also be conclusive for TURP as it results 
in hypovascularized fibrotic tissue with reduced capacity 
of  wound healing after additional radiation [26,27]. The 
combination of BT and EBRT also significantly increases 
the rates of strictures compared to BT or EBRT alone [28].
STRICTURE LOCATION
Typically urethral stricture after primary RT of  the 
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prostate appear in the bulbomembranous urethra (BM, 
>90%), mostly at or below the apex, even though theoretically 
receiving lower radiation dose compared to intraprostatic 
urethra where strictures are rarely seen [4,26]. The radiation 
sensitivity of the BM urethra is not well understood yet. 
Mohammed et al. [18] described a hot spot distally the bulbar 
urethra due to the cylindric volume in patients treated with 
HDR-BT. After a change of  software in 2004 decreasing 
the dosage at the apex of the prostate he observed lower 
stricture rates (9% vs. 0%, p=0.04). Another explanation is 
caudal needle sipping during HDR-BT, however Hindson 
et al. [16] did not observe a decrease of stricture rates after 
replanning in cases of a caudal movement seen in computed 
tomography scan. However, as far as a proper coverage of 
target is achieved, the sparing of the prostatic apical urethra 
appears to be important to decrease the risk of stricture 
formation.
URETHRAL STRICTURE AFTER RADIO-
THERAPY
Postprostatectomy strictures are more often anastomotic 
strictures than urethral strictures, often imprecisely 
mixed with bladder neck obstruction (BNC). The published 
incidence rates of BNC after RP vary from 0%–10% but are 
decreasing with the use of modern technologies like robotic 
surgery (5.1% for open RP, 1.1% for laparoscopic RP, and 
1.4% for robot-assisted laparoscopic radical prostatectomy 
[RLRP]) [29]. Risk factors are well described as multiple 
previous interventions, urinary leakage, adjuvant RT (up 
to >40%), ischemia and surgeon experience [30-33]. All these 
risk factors seem to have a compromised wound healing 
in common. As a result fibrotic tissue narrows the bladder 
neck. In contrast to post RT strictures anastomotic stricture 
due to RP develop within 2–8 months after surgery.
DIAGNOSIS
Usually patients present with typical lower urinary tract 
symptoms (LUTS). As mentioned the time to presentation is 
earlier after RP (2–8 months) compared to RT (1–3 years). 
Work-up is similar to “normal” LUTS including history 
taking (to rule out radiation cystitis), examination, urine 
analyses, uroflow, sonographie and antegrade and retrograde 
urethrographie (RUG). Specific care should be taken to 
prostate-specific antigen level to allow diagnosis of  local 
recurrence. Antegrade and RUG allow determining stricture 
length and a cystoscopy the evaluation of the appearance of 
the urethral mucosa and stricture characteristics, especially 
if planning a urethroplasty. 
MANAGEMENT OF RADIOTHERAPY-
INDUCED URETHRAL STRICTURES
A major challenge in treatment of  radiation induced 
strictures is the urethral tissue damage with reduced healing 
capacity, not only of  the strictures area itself  but also 
proximal and distal of the scar. Moreover the close relation 
to the sphincter can complicate surgery. Management can be 
performed as endoscopic surgery and open urethroplasty.
DILATION AND DIRECT VISION INTER-
NAL URETHROTOMY
Data from nonirradiated urethral strictures treated with 
dilatation and/or direct vision internal urethrotomy (DVIU) 
show a close correlation between the length of stricture and 
treatment response, as strictures <1 cm have higher success 
rates (50%–85%) compared to >1 cm (6%–40%). However, 
success rates decline progressively with longer follow-up [34-
36].
Table 1. Stricture free rates after prostate cancer therapy
Primary treatment 6 Months 1 Year 2 Years 4 Years
RP 93 (92–94) 91 (90–93) 91 (89–92) 89 (86–91)
RP+EBRT 97 (88–99) 95 (85–98) 95 (85–98) 86 (46–97)
Cryotherapy 96 (92–98) 96 (92–98) 95 (89–98) 87 (66–95)
BT 96 (94–97) 94 (92–96) 93 (90–95) 89 (80–94)
BT+EBRT 96 (92–98) 92 (87–95) 88 (91–93) 84 (71–92)
EBRT 99 (97–99) 98 (96–99) 96 (93–97) 95 (90–98)
Hormones 96 (94–97) 94 (92–96) 93 (90–95) 92 (87–95)
WW 99 (97–100) 99 (97–100) 98 (95–99) 93 (68–99)
Values are presented as % stricture treatment free (95% confidence interval).
RP, radical prostatectomy; EBRT, external beam radiotherapy; BT, brachytherapy; WW, watchful waiting.
Adapted from Elliott et al. J Urol 2007;178:529-34, with permission of Elsevier [19].
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Brandes [37] reviewed their experience in men treated 
with dilatation or DVIU with radiation induced strictures 
(BT, EBRT, combination of both modalities) and report about 
a mean stricture length of 2.5 cm. Interestingly, the authors 
described completely different success rates according to the 
different radiation techniques. After BT they found a mean 
time to recurrence of 3.7 months, while this was increased to 
26 months after EBRT. For nonradiation related 2- to 4-cm 
strictures recurrence rates of 50% at 12 months and 75% 
after 48 months are described. They concluded that the high 
failure rates are more probably due to high dose fraction 
of radiation rather than stricture length itself, as results 
after EBRT appeared to be comparable to nonirradiated 
strictures. However, the success rates after 4 years are poor 
(BT, 0%; EBRT, 20%). Even worse data is reported after the 
combination of both techniques with longer median stricture 
length (3.5 cm), shorter time to diagnosis (10.9 months) 
and higher failure rate after dilatation and/or DVIU. In 
conclusion, Brandes [37] stated: “As successive urethrotomy 
or dilation is short-lived and palliative, 80% of the patients 
require repeat treatment and most more than three”.
Moreover, repeated conservative treatments complicate 
stricture characteristics and delay time to def initive 
urethroplasty.
OPEN RECONSTRUCTION
The options for open reconstruction include stricture 
excision and primary anastomosis (EPA), buccal mucosa 
graft urethroplasty and flap reconstruction. The accurate 
diagnostics and careful patient selection are necessary for 
the selection of the best surgical technique and therefore 
successful treatment. Again, all techniques have to be 
performed in radiation damaged hypovascularized and 
hypoxic tissue with a decreased availability of tissue healing. 
When considering these principles, high success rates can be 
achieved, especially after EPA for short strictures.
1. Stricture EPA
Recently, Rourke et al. [38] published their results for 35 
patients who underwent urethroplasty for radiation induced 
(20 patients after EBRT, 15 after BT) bulbomembranous 
stenosis with a mean length of  3.5 cm. For the majority 
(65.7%) EPA was performed, while the rest required buccal 
mucosa graft or penile flap. After a follow-up of 4 years 
cystoscopic patency was almost 86% with no difference 
between techniques. In contrast to most series they also 
documented complications: 31.4% experienced 90-day 
complication, all of  them relatively mild Clavien-Dindo 
grades I–II. From these patients 25.7% complained about 
a new or impairment of a pre-existing incontinence. The 
rate decreased to 13.3 if patients having a prior TURP were 
excluded. While incontinence in patients without TURP 
was managed mostly with anticholinergics, incontinence in 
patients with prior TURP required intervention due to its 
sphincteric etiology (Table 2).
In the largest study examining the outcome of  men 
treated for RT induced strictures Hofer et al. [39] examined 
72 patients. Of these 42% received BT, 42% received EBRT 
and 14% a combination of both modalities and presented 
with a mean stricture length of  2.3 cm. The majority of 
the patients (n=66) were treated with EPA. Intervention 
was successful in 70% of the patients. The median time to 
recurrence was around 10 months and 18.5% complained 
about incontinence. Worsened continence might be explained 
by the close relationship to the external sphincter in 
combination with an impaired bladder (e.g., radiation cystitis, 
low compliance bladder) function.
In contrast to Rourkes, but in consensus to other author’s 
data, the rate of  erectile dysfunction remained stable 
(preoperative, 45.6%; postoperative, 50.9%) (Table 2) [39].
Technically surgery is performed as in nonradiation 
strictures, however the intervention is demanding because of 
the radiation damages fibrotic tissue, the close relationship 
to the sphincter and reduced healing capacity. Fibrotic and 
necrotic tissue should be removed before a tension free 
anastomosis of “healthy” mucosa and surrounding tissue is 
Table 2. Characteristics after intervention for irradiation induced strictures
Source
No. of 
patients
Location
Mean length 
(cm)
Intervention
F/U 
(yr)
Success definition
Success rate 
(%)
Time to  
recurrence (mo)
Rourke et al. [38] 35 BM 2.1
6.1
EPA (65%)
Graft/flap (35%)
4 Patency 91
75
29.8
Hofer et al. [39] 72 B & BM 2.4
4.25
EPA (92%)
Graft/flap (8%)
3.5
5.5
≤16 Fr on cystoscopy 69.7
85
10.1
7
Ahyai et al. [40] 38 B & BM 2.9 BMGU 2.2 Remanipulation or intervention 71.1 17
F/U, follow-up;  BM, bulbo-membranous; B, bulbar; EPA, excision and primary anastomosis; BMGU, buccal mucosa graft urethroplasty.
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performed.
The selection of surgical intervention is an individual 
decision. However, after comparing the better long-term 
outcome data after EPA to those after tissue transfer (see 
below) EPA should be the first option for short strictures 
with few surrounding scar tissue distant from the sphincter. 
2. Tissue transfer
Tissue transfer techniques include buccal and penile 
skin graft. The indication is usually based on stricture 
length. However, published data are controversial as some 
groups perform EPA up to 3 cm [39], while others perform 
tissue transfer for strictures longer the 1 or 2 cm. Generally 
speaking tissue transfer surgery has to deal with the same 
limitation due to the previous radiation exposure as EPA.
Ahyai et al. [40] recently published a series of 38 men 
receiving buccal mucosa graft urethroplasty for strictures 
after RT (64.9% EBRT, 21.6% BT, 13.5% a combination of both 
modalities) in Hamburg/Germany. Strictures were located 
in the BM urethra with a median length of 3 cm (range, 
1–8 cm). After a median follow up of 2 years they described 
an overall success rate of 71% (Table 2). While the overall 
success rates are comparable to published EPA results, the 
recurrence rates increased over time. They observed success 
rates of  90%, 76%, and 39% after 1, 3, and 4 years after 
buccal mucosa graft urethroplasty, respectively [40]. This 
unsatisfying medium term results reported from a center of 
excellence in urethroplasty clearly indicate the difficulties 
in treating radiation therapy induced urethral strictures.
COMMENT
Many patients are treated with RT for localized prostate 
cancer. After treatment radiation induced stricture of the 
urethra is a severe long-term side effect, as radiation damage 
may result in vasculare atrophy, poorly oxygenated tissue 
and/or collagen deposition with eventual tissue scarring. 
The decreased availability of tissue healing and the close 
relation to the sphincter complicates any surgical approach. 
According to dilatation and/or DVIU results are poor. If 
open surgery is planned, the careful evaluation of the actual 
stricture, patient counseling and patient selection are basic 
requirements for a successful treatment. The surgeon should 
be experienced with all the techniques of  open stricture 
surgery. Even in experienced hands, success rates decrease 
with the extent of tissue damage and stricture length. For 
short strictures EPA should be the first choice, as onlay 
techniques are required for longer strictures. Patients 
undergoing surgery should be informed about the chances 
of stricture recurrence. Moreover they need to know about a 
new or impairment of a pre-existing incontinence, especially 
for membranous strictures or after previous TURP or RP. 
Nonsuitable patients should be informed about alternative 
(palliative) methods such as intermittent self-catheterization. 
A continent vesicostomy or urinary diversion might be 
an alternative for patients with devastated bladder outlet 
(combination of stricture and incontinence).
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